(M3) AMCP Market Insights: Targeted Therapies to Deliver Improved Patient Outcomes in Oncology

This session is sponsored by Seagen and is not accredited for continuing pharmacy education credit.

As the US Market continues to evolve, so does the complexity of payers and providers navigating best practices that ensure their members have access to high-quality, cost-effective medications. AMCP’s Market Insights Best Practice provides recommendations from our managed care members to help their peers make the best coverage and access decisions. Oncology is seeing accelerated development of new expression-based therapy classes with the potential to deliver unprecedented improvements in patient outcomes. One class of particular interest are antibody-drug conjugates (ADCs). ADCs are amongst the fastest growing drug classes in oncology, as they combine the best features of monoclonal anti-bodies and small molecule drugs, creating a single moiety that is highly specific and cytotoxic. Managed care and payer professionals play a central role in improving value in and access to cancer care. Understanding best practices that address the multidimensional system challenges can support identifying which health services are safe, efficacious, and cost-effective, address barriers to high-quality care, and better understand the patient experience in the health care system.